Full Description
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the obesity and metabolic syndrome epidemics, which this up-to-date book deals with comprehensively. The contents outline disease mechanisms, diagnostic tests, management, varying manifestations, and special populations. It covers the mechanistic pathways that contribute to NAFLD development, including the role of genetic variants and the gut microbiome. It elaborates on noninvasive diagnostic tests to screen for NAFLD, determine its severity, and monitor response to lifestyle intervention and pharmacologic treatment. This book helps clinicians diagnose and treat this common and potentially deadly disease.
Key Features:
Reviews current drugs in development and provides practical advice to clinicians on the diagnosis and management of fatty liver.
Proves attractive to primary care providers who are on the front line of managing patients with NAFLD, to gastroenterologists and hepatologists who would benefit from updated data on how to risk-stratify patients and identify those who will be eligible for pharmacologic treatment, and other specialists such as cardiologists, endocrinologists, and nephrologists who will find this book to be a useful reference on the extrahepatic manifestations of NAFLD.
Focuses on extrahepatic manifestations and new insights on the mechanistic drivers of the disease.
Contents
Preface
Section 1. Mechanisms of NAFLD Development
1.Historical Perspectives and Clinical Presentation. 2.Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. 3.Genetics of NAFLD. 4.Mechanisms of hepatocyte injury and inflammation in NAFLD. 5.The role of the microbiome.
Section 2. Diagnostic Tests
6.Simple Algorithms in Primary Care. 7.Ultrasound based techniques in NAFLD. 8.MRI-based technologies. 9.Artificial intelligence in NAFLD diagnosis.
Section 3. Management
10.Dietary interventions. 11.Weight Loss Medications. 12.De novo lipogenesis inhibitors. 13.Targeting bile acids (FXRs and FGF19). 14.PPAR agonists. 15.Anti-inflammatory drugs: Metabolic inflammation in NASH as a therapeutic target. 16.Practical Aspects of Pharmacologic Management.
Section 4. Extrahepatic Manifestations
17.Endocrinology: Diabetes and other endocrinopathies. 18.Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease. 19.Extrahepatic Gastrointestinal Manifestations of Non-alcoholic Fatty Liver Disease. 20.Extrahepatic and Hepatic cancers.
Section 5. NAFLD in special populations
21.NAFLD in Children: Unique Aspects and Controversies. 22.NAFLD in HIV patients. 23.NAFLD in Liver Transplant Recipients. 24.NAFLD in lean individuals.
